Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-03-02
2001-01-23
Woodward, Michael P. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S558000, C514S559000, C514S474000, C549S315000
Reexamination Certificate
active
06177470
ABSTRACT:
The invention relates to ascorbic acid (Vit. C) derivatives of fatty acids.
Ascorbic acid derivatives of fatty acids (1) are known, where R is a fatty acid chain and R
1
=H or R.
Thus Kaneko et al Arch. Biochm. Biophys. 304 No. 1,176-180, (1993) report protective action against the cytoxicity of linoleic acid hydroperoxide in human cell cultures, shown by 6-0-palmitoyl, 6-0-stearoyl and 2,6-0-dipalmitoyl ester and 2-0-octadecyl ether derivatives of ascorbic acid. Similarly the preparation of ascorbyl docosahexaenoate has been described.
Further, unsaturated fatty acids have been protected from atmospheric oxidation by ascorbic acid used with phosphorylated mono- or di-fatty acyl glycerides, the ascorbic acid optionally being in the form of a palmitate or stearate (Cloughley, EPA 93304827.4, based on UK 92 13322.2).
Also, the idea of co-administering gamma-linolenic acid (GLA) or dihomo-gamma-linolenic acid (DGLA) with ascorbic acid has been published in a number of previous applications by the inventors, for example EPA 0 019 423 and EPA 0 085 579.
Generally however little attention has been paid to ascorbate esters of fatty acids though Kanebo in JP-A-62 081307 discloses GLA esters of ascorbic acid in cosmetic compositions.
Ascorbic acid is of course well known as a water-soluble vitamin essential for health. Less remarked is the fact that ascorbic acid is able to stimulate the conversion of DGLA to prostaglandin E
1
(PGE
1
). PGE
1
is a short lived substance which has an exceptionally wide range of desirable effects. It dilates blood vessels and bronchi and bronchioles, inhibits platelet aggregation, exerts anti-inflammatory effects, lowers cholesterol levels, lowers blood pressure, and is believed to have a range of other desirable actions including anti-cancer and anti-metastatic effects.
In view of the desirable effects of PGE
1
optimum conditions should exist for its formation in the body. One way of seeking to ensure this is to increase intake of DGLA or its immediate precursor GLA. Another is to provide appropriate levels of ascorbic acid to encourage the formation of PGE
1
.
We now find that it is specifically advantageous to give GLA and DGLA as their ascorbic-6-acid esters subsequently referred to as Ascorbyl GLA and Ascorbyl DGLA. These compounds can be synthesised by the reaction of the acid chloride or anhydride of the fatty acid in the presence of a mineral acid catalyst i.e. hydrogen chloride, in a suitable solvent e.g. dimethyl acetamide/dichloromethane at a temperature between −10° C. and 30° C. as described herein. They have pharmaceutical uses in many conditions and the invention extends to their use in such conditions and in the preparation of medicaments for the purpose. The conditions include:
(a) asthma and related disorders, where PGE
1
is an effective and safe bronchodilator and anti-inflammatory agent and is likely to have a particularly desirable effect both in dilating airways and, in the longer term, suppressing the airway inflammation that is now recognised as a major factor in asthma
(b) cardiovascular disorders associated with atherosclerosis, and/or elevated cholesterol, and/or hypertension, and/or excessive platelet aggregation
(c) rheumatoid arthritis, osteoarthritis, dermatitis and other inflammatory disorders
(d) cancer
Uses also extend to cosmetic or skin care preparations and also to foods of any type but particularly nutritional supplements.
The particular valve of ascorbyl DGLA is the provision at the same time and in precisely the same place both the immediate substrate, DGLA, for PGE
1
biosynthesis and a stimulating agent, ascorbate which will enhance the conversion of the substrate DGLA to PGE
1
. As far as we are aware the compound ascorbyl-DGLA has never previously been described.
The ester may be administered orally, enterally or parenterally in capsules, tablets, sachets, solutions, emulsions, powders, liposomes or other forms in doses of 0.1 mg to 50 g per day, preferably 10 mg to 10 g and very preferably 100 mg to 5 g per day. The ester may also be applied topically in creams, ointments, lotions, emulsions, pessaries, suppositories, sticks or other appropriate forms in which the compound is present in a concentration of 0.001% to 50%, preferably 0.1% to 20% and very preferably 1% to 10% by weight. Similar concentrations may be used to deliver aerosols, liposomes or other appropriate delivery systems which will ensure delivery of the drug directly to the airways.
A particular appropriate formulation is for the ester to be dissolved or dispersed in free fatty acids or triglycerides in which one or more of GLA, DGLA and/or the further anti-inflammatory fatty acid EPA is an important constituent preferably 5% or more by weight. Particularly suitable triglycerides are ones containing 1, 2 or 3 moieties selected from GLA, DGLA and EPA.
REFERENCES:
patent: 4388324 (1983-06-01), Horrobin
patent: 4938960 (1990-07-01), Ismail
patent: 5078989 (1992-01-01), Ando et al.
patent: 5122536 (1992-06-01), Perricone
patent: 5328691 (1994-07-01), Horrobin et al.
patent: 5591446 (1997-01-01), Melnik et al.
patent: 5618558 (1997-04-01), Horrobin et al.
patent: 339632 (1959-07-01), None
patent: 639776 (1936-12-01), None
patent: 1231848 (1968-01-01), None
patent: 0 019 423 (1980-11-01), None
patent: 0 037 175 (1981-10-01), None
patent: 0 087 864 (1983-09-01), None
patent: 0 115 419 (1984-08-01), None
patent: 0 440 307 A2 (1991-08-01), None
patent: 0 577 305 A1 (1994-01-01), None
patent: 991390 (1965-05-01), None
patent: 1 580 444 (1980-12-01), None
patent: 2 134 782 (1984-08-01), None
patent: WO 93/06812 (1993-04-01), None
Cameron et al., Effects of chronic ascorbyl-&ggr;-linoleic acid treatment on sciatic nerve blood flow and conduction in anaesthetized diabetic rats. Abstracts of The Physiological Society, King's College, London. Abstract C46, p. 39P. (Dec. 1995).
“Organic Chemistry” third edition (1984), 22.1 Fatty Acids and Gyceryl Trialkanoates, p. 977. No month found.
Database WPI Derwent AN 84-123435; PN JP-A-59059612, abstract only. (Apr. 1984).
Database WPI Derwent AN 89-140904 & JP-A-62081307, abstract only. (Apr. 1987).
Patent Abstracts of Japan vol. 17, No. 647 (C-1135); JP-A-05 208 968, abstract only.
Database WPI Derwent AN 93-308332; JP-A-5 219 970 abstract & structure only.
Database WPI Derwent AN 91-167165, JP-A-3 099 073, abstract only & structure.
Database WPI Derwent AN 89-141203, JP-A-1 085 907, abstract & structure only.
Med Hypotheses vol. 5, No. 8, 1979 pp. 849-858 Horrobin “The regulation of prostaglandin E1 formation: a candidate for one of the fundamental mechanisms involved in the actions of vitamin C.”
Chemical Abstracts, vol. 55, No. 15, Published in Jul. 24, 1961, Abstract for Cited Swiss Patent 339,632 Provided by Applicants'.
Goodwin, T.W., “The Biosynthesis of Vitamins and Related Compounds”, Academic Press, Published 1963, p. 232. No month found.
Martindale, The Extra Pharmacopoeia, 26th Edition, Blacow et al., Editors, Published in Jul. 1972, p. 1254.
Cousins et al., “Synthesis of 6-Fatty Acid Esters of L-Ascorbic Acid”, The J. of the American Oil Chemists' Society, 54(8), Aug. 1977, pp. 308-312.
Hassall et al., “Dihomo-Gamma-Linolenic Acid Reverses Hypertension Induced in Rats by Diets Rich in Saturated Fat”, Lipids, 19(9), Published in 1984, pp. 699-703. No month given.
Begin et al., “A Deficiency in Dietary Gamma-Linolenic and/or Eicosapentaenoic Acids May Determine Individual Susceptability to AIDS”, Med.-Hypotheses, 20(1), Published in 1986, pp. 1-8. (Abstract). No month given.
McCollum, J.R., “FDA Alert on Evening Primrose Oil”, J. of the American Dietetic Association, vol. 89, No. 5, Issued May 1989, p. 622.
Horrobin David F
Knowles Philip
Manku Mehar S
Moran Marjorie A.
Nixon & Vanderhye
Scotia Holdings PLC
Woodward Michael P.
LandOfFree
Methods of treatment using ascorbyl gamma linolenic acid or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using ascorbyl gamma linolenic acid or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using ascorbyl gamma linolenic acid or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2531282